KLF5 Promotes Tumor Progression and Parp Inhibitor Resistance in Ovarian Cancer

KLF5 Promotes Tumor Progression and Parp Inhibitor Resistance in Ovarian Cancer

Abstract One major characteristic of tumor cells is the aberrant activation of epigenetic regulatory elements, which remodel the tumor transcriptome and ultimately promote cancer progression and drug resistance. However, the oncogenic functions and mechanisms of ovarian cancer (OC) remain elusive. H...

Full description

Bibliographic Details
Main Authors:	Yong Wu, Siyu Chen, Yang Shao, Ying Su, Qin Li, Jiangchun Wu, Jun Zhu, Hao Wen, Yan Huang, Zhong Zheng, Xiaojun Chen, Xingzhu Ju, Shenglin Huang, Xiaohua Wu, Zhixiang Hu
Format:	Article
Language:	English
Published:	Wiley 2023-11-01
Series:	Advanced Science
Subjects:	homologous recombination repair KLF5 ovarian cancer PARPi resistance RAD51 super‐enhancer
Online Access:	https://doi.org/10.1002/advs.202304638

Similar Items

Combinations of ATR, Chk1 and Wee1 Inhibitors with Olaparib Are Active in Olaparib Resistant <i>Brca1</i> Proficient and Deficient Murine Ovarian Cells
by: Michela Chiappa, et al.
Published: (2022-04-01)

The Role of the Rad55–Rad57 Complex in DNA Repair
by: Upasana Roy, et al.
Published: (2021-09-01)

The RAD51-FFPE Test; Calibration of a Functional Homologous Recombination Deficiency Test on Diagnostic Endometrial and Ovarian Tumor Blocks
by: Lise M. van Wijk, et al.
Published: (2021-06-01)

Redox regulation of RAD51 Cys319 and homologous recombination by peroxiredoxin 1
by: John J. Skoko, et al.
Published: (2022-10-01)

Conserved architecture of RAD51 recombinase in ruminants revealed through molecular cloning and characterization
by: SONIKA AHLAWAT, et al.
Published: (2016-12-01)

Unravelling the Role of PARP1 in Homeostasis and Tumorigenesis: Implications for Anti-Cancer Therapies and Overcoming Resistance
by: Taylor Lovsund, et al.
Published: (2023-07-01)

Preventing and Overcoming Resistance to PARP Inhibitors: A Focus on the Clinical Landscape
by: Rosario Prados-Carvajal, et al.
Published: (2021-12-01)

Rad52 Oligomeric N-Terminal Domain Stabilizes Rad51 Nucleoprotein Filaments and Contributes to Their Protection against Srs2
by: Emilie Ma, et al.
Published: (2021-06-01)

PARP Inhibitors for Breast Cancer: Germline <em>BRCA1/2</em> and Beyond
by: Maria Clara Saad Menezes, et al.
Published: (2022-09-01)

VPA and TSA Interrupt the Interplay between mutp53 and HSP70, Leading to CHK1 and RAD51 Down-Regulation and Sensitizing Pancreatic Cancer Cells to AZD2461 PARP Inhibitor
by: Maria Anele Romeo, et al.
Published: (2022-02-01)

A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation
by: Marta Castroviejo‐Bermejo, et al.
Published: (2018-12-01)

METTL3 promotes homologous recombination repair and modulates chemotherapeutic response in breast cancer by regulating the EGF/RAD51 axis
by: Enjie Li, et al.
Published: (2022-05-01)

RAD51 Inhibition Shows Antitumor Activity in Hepatocellular Carcinoma
by: Mingang Pan, et al.
Published: (2023-04-01)

Targeting Homologous Recombination Deficiency in Ovarian Cancer with PARP Inhibitors: Synthetic Lethal Strategies That Impact Overall Survival
by: Tao Xie, et al.
Published: (2022-09-01)

Cooperative interactions facilitate stimulation of Rad51 by the Swi5-Sfr1 auxiliary factor complex
by: Bilge Argunhan, et al.
Published: (2020-03-01)

OsRAD51 Plays a Vital Role in Promoting Homologous Recombination in Rice Meiosis
by: Xiaofei Liu, et al.
Published: (2022-08-01)

Homologous recombination deficiency status predicts response to platinum-based chemotherapy in Chinese patients with high-grade serous ovarian carcinoma
by: Zheng Feng, et al.
Published: (2023-03-01)

The RECAP Test Rapidly and Reliably Identifies Homologous Recombination-Deficient Ovarian Carcinomas
by: Lise M. van Wijk, et al.
Published: (2020-09-01)

Homologous Recombination Deficiency in Ovarian Cancer: from the Biological Rationale to Current Diagnostic Approaches
by: Alessandro Mangogna, et al.
Published: (2023-02-01)

KIAA1529 regulates RAD51 expression to confer PARP inhibitors resistance in ovarian cancer
by: Yuan Qiao, et al.
Published: (2022-10-01)

Regulation of RAD51 at the Transcriptional and Functional Levels: What Prospects for Cancer Therapy?
by: Esin Orhan, et al.
Published: (2021-06-01)

Understanding Rad51 function is a prerequisite for progress in cancer research
by: Bengt Nordén, et al.
Published: (2020-01-01)

Non-Recombinogenic Functions of Rad51, BRCA2, and Rad52 in DNA Damage Tolerance
by: Félix Prado
Published: (2021-09-01)

Clinical application of PARP inhibitors in ovarian cancer: from molecular mechanisms to the current status
by: Yongsong Wu, et al.
Published: (2023-01-01)

RAD51-Mediated DNA Homologous Recombination Is Independent of <i>PTEN</i> Mutational Status
by: Asha Sinha, et al.
Published: (2020-10-01)

Rad52-Rad51 association is essential to protect Rad51 filaments against Srs2, but facultative for filament formation
by: Emilie Ma, et al.
Published: (2018-07-01)

CX-5461 can destabilize replication forks in PARP inhibitor-resistant models of ovarian cancer
by: Jiachen Xuan, et al.
Published: (2020-11-01)

A Pan-Canadian Consensus Statement on First-Line PARP Inhibitor Maintenance for Advanced, High-Grade Serous and Endometrioid Tubal, Ovarian, and Primary Peritoneal Cancers
by: Anna V. Tinker, et al.
Published: (2022-06-01)

Hydroxygenkwanin Increases the Sensitivity of Liver Cancer Cells to Chemotherapy by Inhibiting DNA Damage Response in Mouse Xenograft Models
by: Chin-Chuan Chen, et al.
Published: (2021-09-01)

Subsequent management and outcomes after first-line PARP inhibitors progression in ovarian cancer patients
by: Hua Yuan, et al.
Published: (2024-04-01)

The Hop2-Mnd1 Complex and Its Regulation of Homologous Recombination
by: Hideo Tsubouchi
Published: (2023-04-01)

Overcoming Platinum and PARP-Inhibitor Resistance in Ovarian Cancer
by: Michelle McMullen, et al.
Published: (2020-06-01)

RAD51 as a biomarker for homologous recombination deficiency in high‐grade serous ovarian carcinoma: robustness and interobserver variability of the RAD51 test
by: Claire JH Kramer, et al.
Published: (2023-11-01)

Prevalence and Prognostic Relevance of Homologous Recombination Repair Gene Mutations in Uterine Serous Carcinoma
by: Lin Dong, et al.
Published: (2022-11-01)

Noncanonical Roles of RAD51
by: Mélissa Thomas, et al.
Published: (2023-04-01)

RAD51AP1 and RAD54L Can Underpin Two Distinct RAD51-Dependent Routes of DNA Damage Repair via Homologous Recombination
by: Platon Selemenakis, et al.
Published: (2022-05-01)

PARP inhibitor era in ovarian cancer treatment: a systematic review and meta-analysis of randomized controlled trials
by: István Baradács, et al.
Published: (2024-02-01)

BRCA2 BRC missense variants disrupt RAD51-dependent DNA repair
by: Judit Jimenez-Sainz, et al.
Published: (2022-09-01)

Quercetin and Isorhamnetin Reduce Benzo[a]pyrene-Induced Genotoxicity by Inducing RAD51 Expression through Downregulation of miR−34a
by: Min Kim, et al.
Published: (2022-10-01)

BRIP1, RAD51C, and RAD51D mutations are associated with high susceptibility to ovarian cancer: mutation prevalence and precise risk estimates based on a pooled analysis of ~30,000 cases
by: Malwina Suszynska, et al.
Published: (2020-05-01)